Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 254-413-8 | CAS number: 39318-18-8
Endpoint summary
Administrative data
Description of key information
No skin sensitisation data of sufficient quality are available for tungsten oxide. However, data are available for tungsten trioxide, which are used for read-across. In a skin sensitisation study conducted on guinea pigs and according to OECD 406, tungsten trioxide was deemed to be not sensitising.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Study period:
- 2002-07-22 to 2002-11-14
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Well documented, scientifically sound study that was conducted in accordance to GLP, OECD guideline 406 and Directive 96/54/EC, B.6, "Skin Sensitisation."
- Justification for type of information:
- 1. HYPOTHESIS FOR THE CATEGORY APPROACH: The hypothesis is that properties are likely to be similar or follow a similar pattern because of the presence of a common metal ion, in this case tungstate.
2. SOURCE AND TARGET CHEMICAL(S) (INCLUDING INFORMATION ON PURITY AND IMPURITIES):
Source: Tungsten trioxide
Target: Tungsten oxide
3. CATEGORY APPROACH JUSTIFICATION: See Annex 3 in CSR
4. DATA MATRIX: See Annex 3 in CSR - Reason / purpose for cross-reference:
- reference to other study
- Reason / purpose for cross-reference:
- read-across: supporting information
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.6 (Skin Sensitisation)
- GLP compliance:
- yes
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- A 2002 guinea pig sensitisation study was available of good quality. Therefore, there is no need to conduct a LLNA study as the guinea pig sensitisation study scientifically fulfills the endpoint. The OECD 406 method provides sensitisation information likely to arise from exposure to test substance via intradermical injection and/or epidermical application to guinea pigs. The guinea pig sensitisation test detects chemicals with moderate to strong sensitisation potential, as well as those with relatively weak sensitisation potential. In such methods activity is measured as a function of challenge-induced dermal hypersensitivity reactions elicited in test animals compared with controls. In addition, guinea pigs have been the animal of choice for predictive sensitisation tests for several decades (way before the LLNA became the test of choice).
The existing guinea pig data submitted here is of good quality as clear results are presented in this robust summary and test methodology followed OECD 406 guidelines, and conducted under GLP. This study it is considered acceptable according to page 266 in ECHA's Chapter r7a on Guidance on Information Requirements and Chemical Safety Assessment. - Species:
- guinea pig
- Strain:
- Dunkin-Hartley
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Harlan Winkelmann, Gartenstrasse 27, D-33178 Borchen
- Age at study initiation: Approximately 5-7 weeks
- Weight at study initiation: 316-404 g
- Housing: Until day 0- housed singly in Makrolon cages type III; From day 0- group caging in plastic containers (6 control or 11 test substance animals per container)
- Diet (eg ad libitum): Altromin Maintenance Diet No. 3122- ad libitum
- Water (eg ad libitum): Tap water offered in Makrolon bottles with stainless steel canules- ad libitum
- Acclimation period: 4 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): Average 22.0 °C (step one), Average 21.9 °C(step two)
- Humidity(%): Average 59.9% (step one), Average 56.4% (step two)
- Air changes (per hr): 12/hr
- Photoperiod (hrs dark / hrs light): 12 dark/12 light (6 am to 6 pm) - Route:
- intradermal and epicutaneous
- Vehicle:
- petrolatum
- Concentration / amount:
- 50% (w/w)
- Route:
- epicutaneous, occlusive
- Vehicle:
- petrolatum
- Concentration / amount:
- 50% (w/w)
- No. of animals per dose:
- 2 x 10 animals for the substance group
2 x 5 animals for the control group - Details on study design:
- RANGE FINDING TESTS: Preliminary test with 2 female guinea pigs. FCA was administered intradermally and immediately after, the test substance was administered (50% in white petrolatum, w/w) epicutaneously to the sites of the intradermal injections to examine possible systemic effects. 7 days later 4 concentrations of the test substance were administered epicutaneously for 24 hours.
MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: 2
- Exposure period: 24 hours (exposure 1), 48 hours (exposure 2)
- Test groups: 2 groups both dosed at 50% w/w
- Control group: Dosed with white petrolatum only
- Site: Shaved, 2 cm x 4 cm filter papers with test substance applied and fixed with non-irritating tape (interscapular region)
- Frequency of applications: Day 0 and day 8
- Duration: 25 days
- Concentrations: 50% w/w or 0% w/w
B. CHALLENGE EXPOSURE
- No. of exposures: 1
- Day(s) of challenge: day 22
- Exposure period: 24 hours
- Test groups: 2 groups both dosed at 50% w/w
- Control group: dosed with white petrolatum only
- Site: Shaved, 2 cm x 2 cm filter papers with test substance applied and fixed with non-irritating tape to the left flanks and vehicle to the right flanks.
- Concentrations:50% w/w
- Evaluation (hr after challenge): 3 hours after end of challenge exposure
OTHER: Intradermal injections of FCA were administered directly before epicutaneous exposures. Also, before the second induction exposure, the animals were pretreated with n-dodecylsulfate, sodium salt (10% in white petrolatum, w/w).
Positive Control: Concentrations of HCA
10 females for the positive control substance group and 5 females for the negative control group.
70% in acetone (v/v) for the 1st epicutaneous induction
70% in acetone (v/v) for the 2nd epicutaneous induction
20% in acetone (v/v) for the challenge exposure - Challenge controls:
- Blind reading of test and control animals. All animals administered 50% in white petrolatum, w/w epicutaneously.
- Positive control substance(s):
- yes
- Remarks:
- hexyl cinnamic aldehyde (HCA)
- Positive control results:
- 7/10 animals (70%) represented also the net rate of animals sensitised by HCA.
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 50 % w/w
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- No positive skin reaction in any animal at any reading time
- Remarks on result:
- no indication of skin sensitisation
- Remarks:
- Reading: 1st reading. Hours after challenge: 24. Group: test group. Dose level: 50 % w/w. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: No positive skin reaction in any animal at any reading time .
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 50% w/w
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- No positive skin reaction in any animal at any reading time
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- Vehicle
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- No positive skin reaction in any animal at any reading time
- Remarks on result:
- no indication of skin sensitisation
- Remarks:
- Hours after challenge: 24 Group: negative control. Dose level: 0 % w/w. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: No positive skin reaction in any animal at any reading time.
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- Vehicle
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- No positive skin reaction in any animal at any reading time
- Remarks on result:
- no indication of skin sensitisation
- Remarks:
- Hours after challenge: 48 Group: negative control. Dose level: 0 % w/w. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: No positive skin reaction in any animal at any reading time.
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 70% HCA for induction and 20% HCA for challenge
- No. with + reactions:
- 7
- Total no. in group:
- 10
- Clinical observations:
- Very slight to severe erythema and/or oedema in 7/10 animals 24 and/or 48 hours after challenge exposure
- Remarks on result:
- positive indication of skin sensitisation
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 70% HCA for induction and 20% HCA for challenge
- No. with + reactions:
- 7
- Total no. in group:
- 10
- Clinical observations:
- Very slight to severe erythema and/or oedema in 7/10 animals 24 and/or 48 hours after challenge exposure
- Remarks on result:
- positive indication of skin sensitisation
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- None of the animals in the test substance group were regarded as sensitised.
- Executive summary:
No skin sensitisation data of sufficient quality are available for tungsten oxide (target substance). However, skin sensitiation toxicity data are available for tungsten trioxide (source substance), which are used for read-across. Due to similar water solubility, in vitro bioaccessibility in synthetic alveolar, lysosomal, and interstitial fluids simulating inhalation exposure, and available toxicity data for the target and source substances, the resulting toxicity potential would also be expected to be similar, so read-across is appropriate between these substances. In addition, read-across is appropriate for this endpoint because the classification and labelling is the same for the source and target substances, the PBT/vPvB profile is the same, and the dose descriptors are, or are expected to be, sufficiently similar. For more details, refer to the read-across category approach description in the Category section of this IUCLID submission or Annex 3 of the CSR.
Reference
Mortality
All animals survived till the end of the study.
Body weight
- Step 1: There were no significant differences in the mean body weights between the animals of the test substance group and those of the control group on Days 0 and 25.
- Step 2: There were no significant differences in the mean body weights between the test substance group and the control group on Day 0. On Day 25 the mean body weight of the test substance group animals was slightly, but statistically, higher than that of the control animals. This was of no biological significance and was regarded as a random event.
General observations
Immediately after the beginning of all epicutaneous exposures (inductions, challenge) the motor activities of all animals were increased. This is due to the dressings which restrict the freedom of movement. Soon afterwards the behaviour was regular again. Except of the observations described above no abnormal behaviour or clinical signs were detected during the experiment in the animals.
Skin reactions after the intradermal FCA administration
Cranial and caudal injection sites: Local irritations were observed in all animals beginning on the day after the injections. The irritations started with local erythema, which became more severe and led to ulcerations. Lesions did not heal until the end of the study. These local alterations are known effects of Freund's adjuvant.
Skin reactions after the first and the second induction exposure
All animals of both groups had severe erythema and oedema in the interscapula region which were attributed to the effects of the adjuvant.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
No skin sensitisation data of sufficient quality are available for tungsten oxide (target substance). However, skin sensitisation data are available for tungsten trioxide (source substance), which are used for read-across. Due to similar water solubility, in vitro bioaccessibility in synthetic sweat fluid simulating dermal exposure, and available toxicity data for the target and source substances, the resulting toxicity potential would also be expected to be similar, so read-across is appropriate between these substances. In addition, read-across is appropriate for this endpoint because the classification and labelling is the same for the source and target substances, the PBT/vPvB profile is the same, and the dose descriptors are, or are expected to be, sufficiently similar or more conservative for the target substance. For more details, refer to the read-across category approach description in the Category section of this IUCLID submission or Annex 3 of the CSR.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Additional information:
Although no study data specifically evaluating the potential respiratory sensitisation effects are available, based on the lack of human case reports indicating that tungsten oxide is a respiratory sensitiser, as well as negative responses observed in both the skin sensitisation and skin irritation animal studies, tungsten oxide is not likely to be a respiratory sensitiser
Justification for classification or non-classification
No skin sensitisation data of sufficient quality are available for tungsten oxide. However, a skin sensitisation test of sufficient quality and tested in accordance with standard methodology are available for tungsten trioxide. The results of this study showed that tungsten trioxide did not cause skin sensitisation in Guinea Pigs. Therefore, based on read-across, no classification is required for the skin sensitisation endpoint for tungsten oxide. No respiratory sensitisation study is available for tungsten oxide. Therefore, classification cannot be made due to lack of data. However, this endpoint is not required for REACH registration.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
